V1RE13 Inhibitors
V1RE13 inhibitors comprise a diverse array of chemical compounds that target specific signaling pathways and biological processes to indirectly decrease the functional activity of V1RE13. For instance, the PI3K/AKT pathway inhibitors, Wortmannin and LY294002, can attenuate the activity of V1RE13 by interfering with crucial cellular functions that are potentially regulated by this protein, such as metabolism, cell proliferation, and survival. Similarly, Rapamycin, an mTOR inhibitor, and PD98059, a MAPK/ERK pathway inhibitor, also contribute to the inhibition of V1RE13's activity by targeting the molecular pathways responsible for protein synthesis, cell growth, and differentiation, which V1RE13 may influence. In the same vein, Triciribine and U0126, which inhibit AKT and MEK1/2 respectively, have the potential to suppress V1RE13 by disrupting the associated cell survival, growth, and MAPK signaling processes.
Additional compounds like SP600125, SB203580, and PP2 target JNK, p38 MAP kinase, and Src family tyrosine kinases respectively, which can lead to reduced V1RE13activity by affecting their corresponding stress response, inflammatory signaling, and tyrosine kinase-dependent pathways. Gefitinib and Dasatinib, known for inhibiting EGFR and multiple tyrosine kinases such as Src, c-Kit, and Bcr-Abl, can also potentially decrease the activity of V1RE13 by blocking signaling cascades related to cellular proliferation and survival where V1RE13 is presumed to be active. Lastly, Sorafenib's action on multiple kinases, including VEGFR, PDGFR, and Raf kinases, suggests a broad-spectrum approach to minimizing V1RE13's function by interfering with angiogenesis and cell proliferation processes. Collectively, these inhibitors demonstrate the intricate network of cellular pathways that V1RE13 could be involved in, and how modulation of these pathways by specific chemical inhibitors can lead to a decrease in V1RE13's functional activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
This is a potent phosphoinositide 3-kinase (PI3K) inhibitor. V1RE13's activity could be indirectly inhibited by Wortmannin's effect on the PI3K/AKT pathway, which is integral to various cellular functions including metabolism, proliferation, cell survival, growth, and angiogenesis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A synthetic molecule functioning as another PI3K inhibitor, LY294002, can indirectly decrease V1RE13 activity by hindering the PI3K/AKT pathway, affecting processes such as cell growth and survival which may be regulated by V1RE13. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting the mTOR pathway, Rapamycin can lead to reduced protein synthesis and cell growth, which may indirectly impact the activity of V1RE13, assuming V1RE13 plays a role in these cellular processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of the MAPK/ERK pathway, PD98059, can indirectly inhibit V1RE13 by blocking the pathway that often contributes to cell proliferation and differentiation, where V1RE13 could be involved. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
This is an AKT inhibitor, which can indirectly result in the inhibition of V1RE13 if it is involved in cell survival and growth signaling pathways regulated by AKT. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, enzymes upstream of ERK in the MAPK pathway. By inhibiting these kinases, U0126 may indirectly decrease V1RE13 activity if V1RE13 is linked to the MAPK signaling processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), SP600125 can indirectly inhibit V1RE13 if it is involved in the JNK signaling pathway related to stress responses and apoptosis. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound inhibits p38 MAP kinase, which is involved in inflammatory responses and stress signaling. If V1RE13 is implicated in such pathways, SB203580 could indirectly lead to its inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. By inhibiting Src kinases, PP2 can indirectly affect V1RE13 activity if V1RE13 is part of signaling pathways that depend on these kinases. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor. It can decrease V1RE13's activity by interfering with the EGFR signaling pathway that may regulate cellular processes such as proliferation, which V1RE13 might influence. | ||||||